Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Sutro Biopharma, Inc.NASDAQ: STRO

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue dips below year-ago levels

Q1 FY2026 revenue of $14.52M fell 16.5% year over year, behind the +49.9% change in trailing-twelve-month revenue. Sequentially, it rose 24.7% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 9 analysts of $48.04M (-53.1%) for the fiscal year ending Dec 2026, a slowdown from the +65.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.52M+24.7% QoQ
Last fiscal yearDec 2025
$102.48M+65.2% YoY
LTMMar 2026
$99.61M+49.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.5%-81.2%-64.7 pp
1 year+65.2%-53.1%-118.3 pp
3-year CAGR+14.8%-27.4%-42.2 pp
5-year CAGR-5.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
102.48M USD
Year-over-year change
+65.2%
4-year CAGR
+13.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +49.9% is the highest of 6, against a peer median of -78.3%.
  • Over three fiscal years its annual growth of +14.8% compares with a peer median of +13.1%.
STRO Competitors
Revenue for STRO and competitors
Company Period LTM YoY 3-year CAGR
STROSutro Biopharma, Inc.LTM Mar 2026$99.61M USD+49.9%+14.8%
DTILPrecision BioSciences, Inc.LTM Mar 2026$45.07M USD-11.9%+10.9%
STTKShattuck Labs, Inc.LTM Mar 2026$1M USD-78.3%+15.3%
CNTBConnect Biopharma Holdings LimitedFY2025$64K USD-99.8%—
IFRXInflaRx N.V.LTM Mar 2026€29.33K EUR-77.4%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD——
PLRXPliant Therapeutics, Inc.LTM Mar 2026$0 USD——
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD——
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 USD-100.0%—
Peer median (excluding STRO) —-78.3%+13.1%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.